Original Articles Open access

Evaluation of the effect of rituximab on fatigue in rheumatoid arthritis using the Chalder Fatigue Scale

Authors

Published
28 October 2026
Issue
Early Access
Section
Original Articles

Abstract

Objective. Fatigue is a frequent extra-articular manifestation of rheumatoid arthritis (RA), with a reported prevalence ranging from 40% to 90%. It affects physical, emotional, and cognitive aspects of daily life and significantly impairs quality of life. Although biologic therapies may improve fatigue, the specific effect of rituximab on this symptom remains insufficiently documented. This study aimed to evaluate the effect of rituximab on fatigue at baseline (M0), 4 months (M4), and 6 months (M6) using the Chalder Fatigue Scale (CFS).

Methods. This prospective, observational, single-center study included patients fulfilling the 2010 American College of Rheumatology/European Alliance of Associations for Rheumatology classification criteria for RA and treated with rituximab. Rituximab was administered as two intravenous infusions (500 mg or 1000 mg) on day 0 and day 15. Fatigue was assessed at M0, M4, and M6 using the CFS, with a score ≥4 indicating clinically significant fatigue. Clinical and biological data were collected at each visit. Statistical analyses were performed using Jamovi version 2.4.14.

Results. Ninety-four patients were included (mean age 57±9 years; 88% female). The median CFS score decreased from 4 [2-6] at M0 to 2 [0-4] at M4 (p<0.001) and remained stable thereafter through M6 (p=0.11 for the M4-M6 comparison). Disease activity improved in parallel, with the Disease Activity Score 28 using C-reactive protein (DAS28-CRP) decreasing from 4.7±1.1 at M0 to 2.9±0.9 at M4 and remaining stable at M6. Functional status assessed by Health Assessment Questionnaire also improved significantly. In multivariable analysis, higher M0 DAS28-CRP was associated with a greater reduction in fatigue.

Conclusions. Rituximab therapy was associated with a significant improvement in fatigue in patients with RA, parallel to reductions in disease activity and functional disability.

Ethics Approval

This study was approved by the Ethics Committee for Biomedical Research of Mohammed V University, Faculty of Medicine and Pharmacy of Rabat (reference number: 142-25).

References

  1. Druce KL, Jones GT, Macfarlane GJ, Basu N. Patients receiving anti-TNF therapies experience reduced fatigue in rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register for Rheumatoid Arthritis. Rheumatology 2015; 54: 964-71. DOI: https://doi.org/10.1093/rheumatology/keu390
  2. Nikolaus S, Bode C, Taal E, van de Laar MAFJ. Fatigue and factors related to fatigue in rheumatoid arthritis: a systematic review. Arthritis Care Res 2013; 65: 1128-46. DOI: https://doi.org/10.1002/acr.21949
  3. Hewlett S, Chalder T, Choy E, Cramp F, Davis B, Dures E, et al. Fatigue in rheumatoid arthritis: time for a conceptual model. Rheumatology 2011; 50: 1004-6. DOI: https://doi.org/10.1093/rheumatology/keq282
  4. Pollard LC, Choy EH, Gonzalez J, Khoshaba B, Scott DL. Fatigue in rheumatoid arthritis reflects pain, not disease activity. Rheumatology 2006; 45: 885-9. DOI: https://doi.org/10.1093/rheumatology/kel021
  5. Minnock P, Kirwan J, Bresnihan B. Fatigue is a reliable, sensitive and unique outcome measure in rheumatoid arthritis. Rheumatology 2009; 48: 1533-6. DOI: https://doi.org/10.1093/rheumatology/kep287
  6. van Steenbergen HW, Tsonaka R, Huizinga TWJ, et al. Fatigue in rheumatoid arthritis: a persistent problem. RMD Open 2015; 1: e000041. DOI: https://doi.org/10.1136/rmdopen-2014-000041
  7. Katz P, Margaretten M, Trupin L, Schmajuk G, Yazdany J, Yelin E. Role of sleep disturbance, depression, obesity, and physical inactivity in fatigue in rheumatoid arthritis. Arthritis Care Res 2016; 68: 81-90. DOI: https://doi.org/10.1002/acr.22577
  8. Matcham F, Ali S, Hotopf M, Chalder T. Psychological correlates of fatigue in rheumatoid arthritis: a systematic review. Clin Exp Rheumatol 2015; 33: 305-15. DOI: https://doi.org/10.1016/j.cpr.2015.03.004
  9. van Hoogmoed D, Fransen J, Bleijenberg G, van Riel P. Physical and psychosocial correlates of severe fatigue in rheumatoid arthritis. Rheumatology 2010; 49: 1294-302. DOI: https://doi.org/10.1093/rheumatology/keq043
  10. Tournadre A, Pereira B, Gossec L, Soubrier M, Dougados M. Impact of comorbidities on fatigue in rheumatoid arthritis patients: results from a nurse-led program for comorbidities management (COMEDRA). Joint Bone Spine 2019; 86: 55-60. DOI: https://doi.org/10.1016/j.jbspin.2018.06.010
  11. Almeida C, Choy EH, Hewlett S, Kirwan JR, Cramp F, Chalder T, et al. Biologic interventions for fatigue in rheumatoid arthritis. Cochrane Database Syst Rev 2016; 6: CD008334. DOI: https://doi.org/10.1002/14651858.CD008334.pub2
  12. Pope JE. Management of fatigue in rheumatoid arthritis. RMD Open 2020; 6: e001084. DOI: https://doi.org/10.1136/rmdopen-2019-001084
  13. Edwards JCW, Szczepanski L, Szechinski J, Filipowicz-Sosnowska A, Emery P, Close DR, et al. Efficacy of B-cell-targeted therapy with rituximab in patients with rheumatoid arthritis. N Engl J Med 2004; 350: 2572-81. DOI: https://doi.org/10.1056/NEJMoa032534
  14. van Vollenhoven RF, Emery P, Bingham CO 3rd, Keystone EC, Fleischmann RM, Furst DE, et al. Long-term safety of rituximab in rheumatoid arthritis: 9.5-year follow-up of the global clinical trial programme with a focus on adverse events of interest in RA patients. Ann Rheum Dis 2013; 72: 1496-502. DOI: https://doi.org/10.1136/annrheumdis-2012-201956
  15. Chalder T, Berelowitz G, Pawlikowska T, Watts L, Wessely S, Wright D, Wallace EP. Development of a fatigue scale. J Psychosom Res 1993; 37: 147-53. DOI: https://doi.org/10.1016/0022-3999(93)90081-P
  16. McIlvenny S, Ahmed MH, Dunn E, Swadi H, Balshie M. The translation into Arabic and revalidation of a fatigue questionnaire. East Mediterr Health J 1999; 5: 503-14. DOI: https://doi.org/10.26719/1999.5.3.503
  17. Cohen J. Statistical power analysis for the behavioral sciences. 2nd ed. Hillsdale, NJ, USA: Lawrence Erlbaum Associates; 1988.
  18. Keystone E, Burmester GR, Furie R, Loveless JE, Emery P, Kremer J, et al. Improvement in patient-reported outcomes in a rituximab trial in patients with severe rheumatoid arthritis refractory to anti-tumor necrosis factor therapy. Arthritis Rheum 2008; 59: 785-93. DOI: https://doi.org/10.1002/art.23715
  19. Harrold LR, John A, Best J, et al. Impact of rituximab on patient-reported outcomes in patients with rheumatoid arthritis from the US Corrona Registry. Clin Rheumatol 2017; 36: 2135-40. DOI: https://doi.org/10.1007/s10067-017-3742-2
  20. Gossec L, Danré A, Combe B, Le Loët X, Tebib J, Sibilia J, et al. Improvement in patient-reported outcomes after rituximab in rheumatoid arthritis patients: an open-label assessment of 175 patients. Joint Bone Spine 2015; 82: 451-4. DOI: https://doi.org/10.1016/j.jbspin.2015.02.007
  21. Rigby W, Ferraccioli G, Greenwald M, Zazueta-Montiel B, Fleischmann R, Wassenberg S, et al. Effect of rituximab on physical function and quality of life in patients with rheumatoid arthritis previously untreated with methotrexate. Arthritis Care Res 2011; 63: 711-20. DOI: https://doi.org/10.1002/acr.20419
  22. Goñi M, Basu N, Murray AD, Waiter GD. Brain predictors of fatigue in rheumatoid arthritis: a machine learning study. PLoS One 2022; 17: e0269952. DOI: https://doi.org/10.1371/journal.pone.0269952

Metrics

Citations and online attention from Dimensions, Altmetric and PlumX.